Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1980 4
1981 4
1982 2
1983 5
1984 2
1985 2
1986 2
1987 4
1988 6
1989 3
1990 4
1991 4
1992 2
1993 2
1994 3
1995 6
1996 5
1997 9
1998 3
2000 6
2001 4
2002 8
2003 4
2004 9
2005 6
2006 3
2007 4
2008 7
2009 1
2010 3
2011 7
2012 8
2013 4
2014 1
2015 3
2016 5
2017 6
2018 7
2019 8
2020 10
2021 5
2022 5
2023 5
2024 5
2025 6
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.
Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, Palevsky PM, Weisberg LS, Schorr CA, Trzeciak S, Walker PM; EUPHRATES Trial Investigators. Dellinger RP, et al. JAMA. 2018 Oct 9;320(14):1455-1463. doi: 10.1001/jama.2018.14618. JAMA. 2018. PMID: 30304428 Free PMC article. Clinical Trial.
IMPORTANCE: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may impr …
IMPORTANCE: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood wi …
Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.
Lakota EA, Landersdorfer CB, Nation RL, Li J, Kaye KS, Rao GG, Forrest A. Lakota EA, et al. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00483-18. doi: 10.1128/AAC.00483-18. Print 2018 Jul. Antimicrob Agents Chemother. 2018. PMID: 29760144 Free PMC article.
Herein we present a polymyxin B therapeutic window based on target area under the concentration-time curve (AUC) values and an adaptive feedback control algorithm (algorithm) which allows for the personalization of polymyxin B dosing. ...A previously d …
Herein we present a polymyxin B therapeutic window based on target area under the concentration-time curve (AUC) values and an …
Polymyxin B Hemoperfusion for Sepsis and Septic Shock: A Systematic Review and Meta-Analysis.
Terayama T, Yamakawa K, Umemura Y, Aihara M, Fujimi S. Terayama T, et al. Surg Infect (Larchmt). 2017 Apr;18(3):225-233. doi: 10.1089/sur.2016.168. Epub 2017 Jan 16. Surg Infect (Larchmt). 2017. PMID: 28092497
BACKGROUND: To evaluate the efficacy and safety of direct hemoperfusion with polymyxin B-immobilized fiber (PMX-DHP) therapy in patients with sepsis. DESIGN: A systematic review and meta-analysis of four major databases: Cochrane Central Register of Controlled Trial …
BACKGROUND: To evaluate the efficacy and safety of direct hemoperfusion with polymyxin B-immobilized fiber (PMX-DHP) therapy i …
Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.
Fujii T, Ganeko R, Kataoka Y, Furukawa TA, Featherstone R, Doi K, Vincent JL, Pasero D, Robert R, Ronco C, Bagshaw SM. Fujii T, et al. Intensive Care Med. 2018 Feb;44(2):167-178. doi: 10.1007/s00134-017-5004-9. Epub 2017 Dec 4. Intensive Care Med. 2018. PMID: 29204670
PURPOSE: Polymyxin B-immobilized hemoperfusion (PMX-HP) is an adjuvant therapy for sepsis or septic shock that clears circulating endotoxin. ...
PURPOSE: Polymyxin B-immobilized hemoperfusion (PMX-HP) is an adjuvant therapy for sepsis or septic shock that clears circulat …
Effectiveness of polymyxin B-immobilized hemoperfusion against sepsis and septic shock: A systematic review and meta-analysis.
Li X, Liu C, Mao Z, Qi S, Song R, Zhou F. Li X, et al. J Crit Care. 2021 Jun;63:187-195. doi: 10.1016/j.jcrc.2020.09.007. Epub 2020 Sep 18. J Crit Care. 2021. PMID: 33012579 Free article.
PURPOSE: To evaluate the efficacy and safety of Polymyxin B-immobilized hemoperfusion (PMX-HP) against sepsis or septic shock. METHODS: We searched databases (PubMed, EMBASE and Cochrane Library) to identify eligible randomized controlled trials (RCTs). ...
PURPOSE: To evaluate the efficacy and safety of Polymyxin B-immobilized hemoperfusion (PMX-HP) against sepsis or septic shock. …
Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence.
Falagas ME, Kyriakidou M, Voulgaris GL, Vokos F, Politi S, Kechagias KS. Falagas ME, et al. J Glob Antimicrob Resist. 2021 Mar;24:342-359. doi: 10.1016/j.jgar.2020.12.026. Epub 2021 Jan 21. J Glob Antimicrob Resist. 2021. PMID: 33486122 Free article. Review.
METHODS: We performed a review and meta-analysis to evaluate the current literature data regarding the effectiveness and safety of intravenous polymyxin B in patients with MDR Gram-negative bacterial infections and the overall mortality and nephrotoxicity in patient …
METHODS: We performed a review and meta-analysis to evaluate the current literature data regarding the effectiveness and safety of intraveno …
Effects of Polymyxin B Hemoperfusion on Mortality in Patients With Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis.
Chang T, Tu YK, Lee CT, Chao A, Huang CH, Wang MJ, Yeh YC. Chang T, et al. Crit Care Med. 2017 Aug;45(8):e858-e864. doi: 10.1097/CCM.0000000000002362. Crit Care Med. 2017. PMID: 28445237 Free PMC article.
OBJECTIVE: Several studies have reported a survival benefit for polymyxin B hemoperfusion treatment in patients with severe sepsis and septic shock. However, recently, a propensity-matched analysis and a randomized controlled trial reported no survival benefit for …
OBJECTIVE: Several studies have reported a survival benefit for polymyxin B hemoperfusion treatment in patients with severe se …
Effectiveness and Safety of Compound Polymyxin B Ointment in Treatment of Burn Wounds: A Meta-analysis.
Lu LC, Chang FY, Lv GZ, Lan SH. Lu LC, et al. J Burn Care Res. 2022 Mar 23;43(2):453-461. doi: 10.1093/jbcr/irab099. J Burn Care Res. 2022. PMID: 34091661
This study aims to investigate the effectiveness of the compound polymyxin B topical agents for the treatment of burn wounds. PubMed, Web of Science, ProQuest, and China National Knowledge Infrastructure databases were searched for articles published until January 2 …
This study aims to investigate the effectiveness of the compound polymyxin B topical agents for the treatment of burn wounds. …
Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial.
Liu S, Wu Y, Qi S, Shao H, Feng M, Xing L, Liu H, Gao Y, Zhu Z, Zhang S, Du Y, Lu Y, Yang J, Chen P, Sun T. Liu S, et al. Crit Care. 2023 Jun 13;27(1):232. doi: 10.1186/s13054-023-04522-6. Crit Care. 2023. PMID: 37312218 Free PMC article. Clinical Trial.
BACKGROUND: The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance. ...TDM was employed to determine if the dose of …
BACKGROUND: The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the …
Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
Vardakas KZ, Falagas ME. Vardakas KZ, et al. Int J Antimicrob Agents. 2017 Feb;49(2):233-238. doi: 10.1016/j.ijantimicag.2016.07.023. Epub 2016 Sep 16. Int J Antimicrob Agents. 2017. PMID: 27686609
Colistin and polymyxin B (PMB) have different pharmacokinetic profiles and minor differences in antimicrobial activities that may result in discrepancies in mortality and nephrotoxicity. ...
Colistin and polymyxin B (PMB) have different pharmacokinetic profiles and minor differences in antimicrobial activities that …
201 results